Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 186692-46-6 | Product Number: R0207
Roscovitine
×
![]()
×
Purity: >98.0%(HPLC)(qNMR)
Synonyms:
- Seliciclib
- CYC 202
- (R)-2-[[6-(Benzylamino)-9-isopropyl-9H-purin-2-yl]amino]butan-1-ol
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 20MG |
$135.00
|
Contact Us | Contact Us | 37 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | R0207 |
| Purity / Analysis Method | >98.0%(HPLC)(qNMR) |
| Molecular Formula / Molecular Weight | C__1__9H__2__6N__6O = 354.46 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (-20°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 186692-46-6 |
| Reaxys Registry Number | 7694281 |
| MDL Number | MFCD02266401 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(qNMR) | min. 98.0 % |
| Specific rotation | +50.0 to +56.0 deg(C=1, CHCL3) |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 108 °C |
| Solubility in water | Insoluble |
| Solubility (soluble in) | Acetone, Ethanol |
GHS
Related Laws:
| RTECS# | EL5610000 |
Transport Information:
| HS Number | 2933.59.8000 |
Application
Roscovitine: A Broad-Range Purine Analog CDK Inhibitor
Cyclin-dependent kinases (CDKs) are key regulatory proteins that control the cell cycle and are therefore promising targets for cancer research. Roscovitine (CYC202) has been reported to be a potent CDK inhibitor that competes for ATP binding sites on these kinases, reducing tumor growth and inducing cell death. Roscovitine inhibits CDK1, CDK2, CDK5, CDK7 and CDK9 (IC50 ~0.2-0.7 µM) but is a poor inhibitor for CDK4, CDK6 and CDK8 (IC50 >100 µM). (The product is for research purpose only.)
References
- Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5
- Inhibition of Cyclin-Dependent Kinases by Purine Analogues: Crystal Structure of Human cdk2 Complexed with Roscovitine
- In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
- Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II-Dependent Transcription and Down-regulation of Mcl-1
- Roscovitine in cancer and other diseases (a review)
Application
Roscovitine: A Cyclin-Dependent Kinase (CDK) Inhibitor
Cyclins and cyclin-dependent kinases (CDKs) are a key component of the regulatory proteins that control the cell cycle. CDK plays a critical role in regulating the cell cycle transition and is primarily involved in the pathogenesis of cancer. Roscovitine (CYC202) is a CDK inhibitor that competes for ATP binding sites on these kinases, thereby reducing tumor growth and inducing cell death. There are reports that roscovitine inhibits CDK1, CDK2, CDK5 and CDK7 and leads to growth arrest and apoptosis of tumor cell lines. Roscovitine does not significantly affect the activity of other protein kinases. Therefore, roscovitine has been used as an anti-mitotic reagent for cell cycle research. (The product is for research purpose only.)
References
- Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5
- In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
- Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials (a review)
- Roscovitine in cancer and other diseases (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.